Omniome Stock

omniome.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $153.29MM

Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy.

Register for Details

For more details on financing and valuation for Omniome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Omniome.

Register Today

Team

Management Team

David Mullarkey
Chief Executive Officer, President & Board Member
Kelly Perez
Senior Vice President of Finance
Arnold Oliphant Ph.D
Chief Technology Officer
Ken Song MD
Executive Chairman
Melissa Tosca
Director, Finance and Accounting

Board Members

David Cruikshank
Kim Kamdar Ph.D
Dan Zabrowski Ph.D
Ken Song MD
Michael Yi
Boris Nikolic MD
Biomatics Capital
David Mullarkey

Other companies like Omniome in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Omniome Raises $60M in Series C Financing | FinSMEs
Omniome, Inc., a San Diego, CA-based developer of an innovative DNA sequencing platform, raised an additional $60m and completed the Series C funding
Updated on: Sep 29, 2023